Suppr超能文献

急性冠状动脉综合征患者中铁的预后评估。

Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.

机构信息

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

出版信息

Clin Cardiol. 2013 Mar;36(3):139-45. doi: 10.1002/clc.22089. Epub 2013 Feb 3.

Abstract

BACKGROUND

The potential of iron to generate reactive oxygen species has motivated a long-standing interest in whether excess iron is causally linked to atherosclerotic heart disease. Circulating catalytic iron ("free" iron) is that which is not bound to transferrin or ferritin and is available to generate reactive oxygen species that may have deleterious vascular effects.

HYPOTHESIS

We hypothesized that increased levels of catalytic iron would be associated with increased cardiovascular events.

METHODS

We investigated the association of catalytic iron with clinical outcomes in 1701 patients with unstable angina, non-ST-segment elevation myocardial infarction (MI), or ST-segment elevation MI who were followed for a median of 10 months. All endpoints were adjudicated by a blinded Clinical End Points Committee.

RESULTS

The median catalytic iron level was significantly higher in those who died, 0.45 µmol/L (0.37, 0.57), compared with survivors, 0.37µmol/L (0.31, 0.46; P = 0.016). Catalytic iron was associated with a stepwise increased risk of death, with the highest quartile at an almost 4-fold risk compared with baseline (hazard ratio: 3.94, P = 0.035), which persisted after adjustment for age, diabetes, prior MI, prior congestive heart failure, ST-segment deviation, creatinine clearance, B-type natriuretic peptide, smoking, and Killip class (adjusted hazard ratio: 3.97, P = 0.036). There was no association between catalytic iron and risk of MI, recurrent ischemia, heart failure, or bleeding.

CONCLUSIONS

Increasing catalytic iron levels were associated with increased all-cause mortality. Although our findings suggest that catalytic iron is not likely to add to available tools as a routine biomarker for risk stratification of recurrent ischemic events, its association with mortality is intriguing and leaves open the question of whether cardiovascular therapeutics aimed at catalytic iron may be useful. The TIMI Study Group has received research grant support from the Muljibhai Patel Society for Research in Nephro-Urology.

摘要

背景

铁产生活性氧的潜力促使人们长期关注过量铁是否与动脉粥样硬化性心脏病有因果关系。循环中的催化铁(“游离”铁)是指未与转铁蛋白或铁蛋白结合且可产生活性氧的铁,这些活性氧可能对血管有有害影响。

假说

我们假设增加的催化铁水平与心血管事件的增加有关。

方法

我们研究了 1701 例不稳定型心绞痛、非 ST 段抬高型心肌梗死(MI)或 ST 段抬高型 MI 患者的催化铁与临床结局的相关性,这些患者的中位随访时间为 10 个月。所有终点均由盲法临床终点委员会裁定。

结果

死亡患者的中位催化铁水平明显较高,为 0.45µmol/L(0.37,0.57),而幸存者为 0.37µmol/L(0.31,0.46;P=0.016)。催化铁与死亡风险呈逐步增加的关系,最高四分位组的死亡风险几乎是基线的 4 倍(危险比:3.94,P=0.035),调整年龄、糖尿病、既往 MI、既往充血性心力衰竭、ST 段偏移、肌酐清除率、B 型利钠肽、吸烟和 Killip 分级后仍然如此(校正危险比:3.97,P=0.036)。催化铁与 MI、复发性缺血、心力衰竭或出血风险之间无关联。

结论

催化铁水平升高与全因死亡率增加有关。尽管我们的研究结果表明,催化铁不太可能作为复发性缺血事件风险分层的常规生物标志物增加现有工具,但它与死亡率的关联令人关注,这就提出了一个问题,即针对催化铁的心血管治疗是否可能有用。TIMI 研究小组已从 Muljibhai Patel 肾脏病和泌尿科研究协会获得研究资助。

相似文献

1
Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.
Clin Cardiol. 2013 Mar;36(3):139-45. doi: 10.1002/clc.22089. Epub 2013 Feb 3.
3
The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome.
Clin Cardiol. 2011 Aug;34(8):507-12. doi: 10.1002/clc.20915. Epub 2011 Jun 29.
7
Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction.
Atherosclerosis. 2012 Apr;221(2):490-5. doi: 10.1016/j.atherosclerosis.2012.01.040. Epub 2012 Feb 1.
8
Soluble CXCL16 predicts long-term mortality in acute coronary syndromes.
Circulation. 2009 Jun 30;119(25):3181-8. doi: 10.1161/CIRCULATIONAHA.108.806877. Epub 2009 Jun 15.
10
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med. 2001 Oct 4;345(14):1014-21. doi: 10.1056/NEJMoa011053.

引用本文的文献

1
2
Increased Levels of Circulating Iron-Albumin Complexes in Peripheral Arterial Disease Patients.
Antioxidants (Basel). 2023 Feb 16;12(2):503. doi: 10.3390/antiox12020503.
4
Increased serum catalytic iron may mediate tissue injury and death in patients with COVID-19.
Sci Rep. 2021 Oct 4;11(1):19618. doi: 10.1038/s41598-021-99142-x.
5
Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention.
J Am Soc Nephrol. 2019 Nov;30(11):2060-2071. doi: 10.1681/ASN.2019060595. Epub 2019 Sep 25.
6
N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction.
J Cardiovasc Transl Res. 2015 Jul;8(5):328-37. doi: 10.1007/s12265-015-9633-5. Epub 2015 Jun 18.
7
Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome.
Mediators Inflamm. 2015;2015:710123. doi: 10.1155/2015/710123. Epub 2015 Mar 19.
8
Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery.
Kidney Int. 2015 May;87(5):1046-54. doi: 10.1038/ki.2014.374. Epub 2015 Jan 7.
9
Plasma catalytic iron, AKI, and death among critically ill patients.
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1849-56. doi: 10.2215/CJN.02840314. Epub 2014 Sep 4.
10
Epidemiological associations between iron and cardiovascular disease and diabetes.
Front Pharmacol. 2014 May 20;5:117. doi: 10.3389/fphar.2014.00117. eCollection 2014.

本文引用的文献

1
Association of catalytic iron with cardiovascular disease.
Am J Cardiol. 2012 Feb 1;109(3):438-42. doi: 10.1016/j.amjcard.2011.09.032. Epub 2011 Nov 8.
2
Red cells, hemoglobin, heme, iron, and atherogenesis.
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1347-53. doi: 10.1161/ATVBAHA.110.206433. Epub 2010 Apr 8.
3
Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes.
EuroIntervention. 2009 Aug;5(3):336-42. doi: 10.4244/v5i3a53.
4
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Clin Chem. 2007 Oct;53(10):1800-7. doi: 10.1373/clinchem.2007.087957. Epub 2007 Aug 23.
5
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Circulation. 2006 Aug 8;114(6):550-7. doi: 10.1161/CIRCULATIONAHA.106.641936. Epub 2006 Jul 31.
7
Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients.
Kidney Int. 2004 Jul;66(1):295-302. doi: 10.1111/j.1523-1755.2004.00731.x.
8
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.
Circulation. 2004 May 11;109(18):2186-90. doi: 10.1161/01.CIR.0000127958.21003.5A. Epub 2004 Apr 26.
9
Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper.
Arterioscler Thromb Vasc Biol. 2004 May;24(5):949-54. doi: 10.1161/01.ATV.0000124892.90999.cb. Epub 2004 Mar 4.
10
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med. 2001 Oct 4;345(14):1014-21. doi: 10.1056/NEJMoa011053.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验